Daniel P. Van Plew
Net Worth

Last updated:

What is Daniel P. Van Plew net worth?

The estimated net worth of Mr. Daniel P. Van Plew is at least $75,188,437 as of 24 Aug 2023. He owns shares worth $12,362,583 as insider, has earned $35,975,854 from insider trading and has received compensation worth at least $26,850,000 in Regeneron Pharmaceuticals, Inc..

What is the salary of Daniel P. Van Plew?

Mr. Daniel P. Van Plew salary is $1,790,000 per year as Executive Vice President and GM of Industrial Operations & Product Supply in Regeneron Pharmaceuticals, Inc..

How old is Daniel P. Van Plew?

Mr. Daniel P. Van Plew is 52 years old, born in 1973.

What stocks does Daniel P. Van Plew currently own?

As insider, Mr. Daniel P. Van Plew owns shares in one company:

Company Title Shares Price per share Total value
Regeneron Pharmaceuticals, Inc. (REGN) Executive Vice President and GM of Industrial Operations & Product Supply 21,508 $574.79 $12,362,583

What does Regeneron Pharmaceuticals, Inc. do?

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma;Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

REGN logo
REGN
Regeneron Pharmaceuticals, Inc.
$574.79

Daniel P. Van Plew insider trading

Regeneron Pharmaceuticals, Inc.

Mr. Daniel P. Van Plew has made 74 insider trades between 2010-2023, according to the Form 4 filled with the SEC. Most recently he sold 300 units of REGN stock worth $251,259 on 24 Aug 2023.

The largest trade he's ever made was exercising 85,579 units of REGN stock on 6 May 2020. As of 24 Aug 2023 he still owns at least 21,508 units of REGN stock.

Transaction Date Security Shares Price per share Total value Source
Sale
Common Stock 300 $837.53 $251,259
Sale
Common Stock 667 $838.37 $559,193
Sale
Common Stock 138 $835.67 $115,322
Sale
Common Stock 625 $836.32 $522,700
Sale
Common Stock 617 $842.66 $519,921
Sale
Common Stock 759 $843.31 $640,072
Sale
Common Stock 2,534 $844.27 $2,139,380
Sale
Common Stock 148 $839.28 $124,213
Sale
Common Stock 46 $840.74 $38,674
Sale
Common Stock 363 $841.15 $305,337
Option
Common Stock 23,125 $381.4 $8,819,875
Option
Non-Qualified Stock Option (right to buy) 23,125 $381.4 $8,819,875
Sale
Common Stock 99 $742.58 $73,515
Sale
Common Stock 101 $743.66 $75,110
Sale
Common Stock 1,164 $746.42 $868,833
Sale
Common Stock 780 $744.56 $580,757
Sale
Common Stock 256 $745.56 $190,863
Sale
Common Stock 3,124 $739.48 $2,310,136
Sale
Common Stock 686 $735.57 $504,601
Sale
Common Stock 1,005 $736.46 $740,142
Sale
Common Stock 373 $737.37 $275,039
Sale
Common Stock 1 $748.17 $748
Sale
Common Stock 1,808 $740.29 $1,338,444
Sale
Common Stock 944 $738.57 $697,210
Sale
Common Stock 629 $747.28 $470,039
Sale
Common Stock 1,002 $741.34 $742,823
Option
Non-Qualified Stock Option (right to buy) 50,000 $378.98 $18,949,000
Option
Common Stock 50,000 $378.98 $18,949,000
Sale
Common Stock 404 $747.2 $301,869
Sale
Common Stock 2,032 $744.61 $1,513,048
Sale
Common Stock 100 $742.79 $74,279
Sale
Common Stock 1,468 $745.51 $1,094,409
Sale
Common Stock 1,100 $743.39 $817,729
Sale
Common Stock 2,782 $746.56 $2,076,930
Option
Common Stock 34,000 $381.92 $12,985,280
Option
Non-Qualified Stock Option (right to buy) 34,000 $381.92 $12,985,280
Sale
Common Stock 1,052 $716.28 $753,527
Sale
Common Stock 87 $709.93 $61,764
Sale
Common Stock 2 $710.25 $1,421
Sale
Common Stock 70 $711.85 $49,830
Sale
Common Stock 110 $712.44 $78,368
Sale
Common Stock 572 $713.67 $408,219
Sale
Common Stock 267 $714.42 $190,750
Sale
Common Stock 861 $715.39 $615,951
Sale
Common Stock 647 $717.59 $464,281
Sale
Common Stock 435 $718.5 $312,548
Sale
Common Stock 159 $719.72 $114,435
Sale
Common Stock 181 $720.41 $130,394
Sale
Common Stock 174 $721.38 $125,520
Sale
Common Stock 79 $722.83 $57,104
Option
Non-Qualified Stock Option (right to buy) 40,000 $555.67 $22,226,800
Option
Common Stock 40,000 $555.67 $22,226,800
Sale
Common Stock 1,176 $617.48 $726,156
Sale
Common Stock 300 $615.2 $184,560
Option
Non-Qualified Stock Option (right to buy) 40,000 $399.66 $15,986,400
Sale
Common Stock 600 $614.53 $368,718
Sale
Common Stock 600 $612.44 $367,464
Sale
Common Stock 800 $611.65 $489,320
Sale
Common Stock 200 $610.41 $122,082
Sale
Common Stock 156 $607.94 $94,839
Sale
Common Stock 1,015 $618.16 $627,432
Sale
Common Stock 400 $609.62 $243,848
Sale
Common Stock 800 $608.29 $486,632
Sale
Common Stock 734 $616.4 $452,438
Option
Common Stock 40,000 $399.66 $15,986,400
Option
Non-Qualified Stock Option (right to buy) 25,000 $270.43 $6,760,750
Sale
Common Stock 6,778 $656.32 $4,448,551
Option
Common Stock 25,000 $270.43 $6,760,750
Sale
Common Stock 6,603 $611.41 $4,037,107
Option
Common Stock 25,000 $270.43 $6,760,750
Option
Non-Qualified Stock Option (right to buy) 25,000 $270.43 $6,760,750
Sale
Common Stock 27,109 N/A N/A
Option
Non-Qualified Stock Option (right to buy) 75,000 N/A N/A
Option
Common Stock 75,000 N/A N/A
Sale
Common Stock 39,583 N/A N/A
Option
Common Stock 85,579 N/A N/A
Option
Non-Qualified Stock Option (right to buy) 85,579 N/A N/A
Sale
Common Stock 15,642 N/A N/A
Option
Common Stock 32,735 N/A N/A
Option
Non-Qualified Stock Option (right to buy) 32,735 N/A N/A
Sale
Common Stock 4,413 N/A N/A
Option
Non-Qualified Stock Option (right to buy) 9,460 N/A N/A
Option
Common Stock 9,460 N/A N/A
Option
Incentive Stock Option (right to buy) 1,921 N/A N/A
Option
Common Stock 1,921 N/A N/A
Sale
Common Stock 5,123 N/A N/A
Option
Non-Qualified Stock Option (right to buy) 11,186 N/A N/A
Option
Common Stock 11,186 N/A N/A
Sale
Common Stock 4,028 N/A N/A
Option
Common Stock 8,700 N/A N/A
Option
Non-Qualified Stock Option (right to buy) 8,700 N/A N/A
Sale
Common Stock 18,370 N/A N/A
Option
Non-Qualified Stock Option (right to buy) 40,050 N/A N/A
Option
Common Stock 40,050 N/A N/A
Sale
Common Stock 9,431 N/A N/A
Option
Non-Qualified Stock Option (right to buy) 20,000 N/A N/A
Option
Common Stock 20,000 N/A N/A
Option
Common Stock 3,264 N/A N/A
Option
Incentive Stock Option (right to buy) 3,264 N/A N/A
Sale
Common Stock 8,575 N/A N/A
Option
Non-Qualified Stock Option (right to buy) 18,700 N/A N/A
Option
Common Stock 18,700 N/A N/A
Sale
Common Stock 6,806 N/A N/A
Option
Common Stock 15,000 N/A N/A
Option
Non-Qualified Stock Option (right to buy) 15,000 N/A N/A
Sale
Common Stock 5,369 N/A N/A
Option
Non-Qualified Stock Option (right to buy) 11,200 N/A N/A
Option
Common Stock 11,200 N/A N/A
Option
Incentive Stock Option (right to buy) 4,705 N/A N/A
Option
Common Stock 4,705 N/A N/A
Sale
Common Stock 23,977 N/A N/A
Option
Non-Qualified Stock Option (right to buy) 52,500 N/A N/A
Option
Common Stock 52,500 N/A N/A
Sale
Common Stock 13,725 N/A N/A
Option
Incentive Stock Option (right to buy) 3,902 N/A N/A
Option
Non-Qualified Stock Option (right to buy) 29,048 N/A N/A
Option
Common Stock 32,950 N/A N/A
Option
Incentive Stock Option (right to buy) 2,050 N/A N/A
Option
Common Stock 2,050 N/A N/A
Sale
Common Stock 18,741 N/A N/A
Option
Non-Qualified Stock Option (right to buy) 30,000 N/A N/A
Option
Common Stock 30,000 N/A N/A
Sale
Common Stock 14,442 N/A N/A
Option
Common Stock 35,216 N/A N/A
Option
Incentive Stock Option (right to buy) 4,784 N/A N/A
Option
Common Stock 4,784 N/A N/A
Option
Non-Qualified Stock Option (right to buy) 25,000 N/A N/A
Option
Common Stock 25,000 N/A N/A
Sale
Common Stock 10,000 N/A N/A
Sale
Common Stock 9,568 N/A N/A
Option
Common Stock 25,000 N/A N/A
Option
Non-Qualified Stock Option (right to buy) 15,432 N/A N/A